ANN ARBOR, Mich., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM) ("Zomedica"), a veterinary pharmaceutical and health
care solutions company, today announced that it has retained PCG Advisory Group, a leading integrated communications firm, to serve
as an advisor for investor relations and social media communications strategies.
“We are very pleased to announce that we have engaged PCG Advisory Group to communicate our story concurrent with
our near term goal to list on a major U.S. exchange,” stated Gerald Solensky Jr., Chief Executive Officer of Zomedica. “The PCG
team is known for their dedication to the U.S. micro and small cap market, their vast network of investors and digital/social media
expertise. The selection of PCG Advisory Group reflects our desire to further support our goals by strategically presenting our
corporate and investor message to a wide audience of U.S. investors via traditional investor relations and social and digital media
initiatives. As we continue to add depth to our product pipeline as well as strategic collaborations, now is the time to ensure the
Zomedica investment case is heard throughout the investment community. We believe that PCG’s broad approach and senior team is the
right partner for raising awareness across the stakeholder spectrum.”
“We look forward to working together with the team at Zomedica to achieve their communications and stakeholder
awareness goals,” said Jeff Ramson, Founder and Chief Executive Officer of PCG Advisory Group. “With a clear focus on developing a
diversified portfolio of diagnostics, devices, innovative drugs, and drug-delivery technologies, Zomedica is well positioned to
capitalize on the growth opportunity in the veterinary pharmaceutical and health care solutions market. We believe Zomedica’s
investment case and outlook for growth, supported by its developing product pipeline while investigating strategies for domestic
and global commercialization, will resonate well across PCG’s networks of investors, bloggers, journalists, and other key
stakeholders. With positive growth potential coinciding with a U.S. investment community focus, we are pleased to embark on a
targeted stakeholder marketing initiative.”
Zomedica has entered into an agreement with PCG Advisory Group (which is subject to approval of the TSX Venture
Exchange (“TSX-V”), the consideration under which shall consist of a monthly fee payable by Zomedica in the amount of US$7,500,
commencing August 14, 2017 for a period of twelve months ending on August 13, 2018. Zomedica may terminate the agreement at any
time after February 14, 2018 upon the provision of 30 days written notice. PCG Advisory Group has also been granted stock options
to acquire up to an aggregate of 75,000 Common Shares of Zomedica. Each of the stock options is exercisable for a one-year term
expiring on August 14, 2019 at price of C$2.75 per Common Share. Such options vest quarterly over a period of one year and shall be
subject to regulatory approval and the provisions of Zomedica's Stock Option Plan.
Zomedica also announces that, pursuant to its stock option plan, it has granted stock options to acquire up to an
aggregate of 1,205,000 Common Shares, of which, 1,100,000 stock options were granted to certain officers of Zomedica. Each of the
stock options is exercisable for a two-year term expiring on August 14, 2019 and exercisable until that time at a price of C$2.75
per Common Share. On August 11, 2017, the last day that the Common Shares traded prior to the granting of the stock options, the
closing price of the Common Shares on the TSX Venture Exchange was C$2.40 per share. The foregoing stock options all vested
immediately upon the date of grant. All of the stock options announced herein (including those granted to PCG Advisory Group), and
any Common Shares issued upon exercise of the stock options, are subject to standard hold period restrictions, including a
four-month hold period under Canadian securities laws expiring on December 15, 2017.
About Zomedica
With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical and health care solutions company
creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.
Zomedica is developing a diversified portfolio to include diagnostics, devices, innovative drugs, and drug-delivery technologies.
With a team comprised of clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower
costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release contains certain "forward-looking information" within
the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan",
"expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or
conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are
reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results,
performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole
or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are
made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ
materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the
results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty
as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to
identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to
maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability
to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement
risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product,
intellectual property protection and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as
exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes
in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue
reliance on forward-looking information.
Investor Relations Contact Shameze Rampertab, CPA, CA srampertab@zomedica.com +1 647.283.3630 PCG Advisory Group Kirin Smith, COO ksmith@pcgadvisory.com +1 646.863.6519 www.pcgadvisory.com Media Contact Andrea Eberle aeberle@zomedica.com +1 734.369.2555